Skip to main content

Autoinflammatory

Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. https://t.co/r5WjYIdmaT https://t.co/gGdhyDKqtC
Dr. John Cush @RheumNow( View Tweet )
Feb 21, 2024
Transcriptome analysis (of PBMCs) looked for differential gene expression btwn 125 SJIA & 92 healthy controls identified 4 key genes (ALDH1A1, CEACAM1, YBX3 and SLC6A8) distinguishing SJIA; & may aid in diagnosis. https://t.co/M6pfajw3U3 https://t.co/VVwrYUJcBH
Dr. John Cush @RheumNow( View Tweet )
Feb 14, 2024
Systematic review of 44 studies looking at treatment of Stills Dz (AOSD), showing that tocilizumab, anakinra & canakinumab therapy are effective in AOSD. Complete remission: - TCZ 80% (57% Steroid D/C) - ANAK 73% (47% GC DC) - CAN 77% (34% GC DC) https://t.co/bFil81GGlJ https://t.co/F5NJ6m1gVF
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2024
JAMA Clinical Challenge - Recurrent Fever, Rash, and Shortness of Breath in a 69-Year-Old. Admited with fever, fatigue, rash, right periorbital swelling, SOB, Palpable purpural, Serositis previously - whats your diagnosis? https://t.co/j6aSGffpPv https://t.co/du6pEo74xp
Dr. John Cush @RheumNow( View Tweet )
Feb 11, 2024

New therapeutic approach for the treatment of sarcoidosis

Eureka Alert!
Jan 23, 2024

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This

Read Article

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/TXJbpD3yB4 https://t.co/QGDaZdqrqz

Dr. John Cush @RheumNow( View Tweet )
Jan 17, 2024
What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/3ssM9fMGCm https://t.co/FWZPx9Cpn7
Dr. John Cush @RheumNow( View Tweet )
Jan 10, 2024
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/gvbPkeq2sH https://t.co/J25U6rWNTy
Dr. John Cush @RheumNow( View Tweet )
Dec 30, 2023
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/vY1yZUX25S

Dr. John Cush @RheumNow( View Tweet )

Dec 29, 2023

StillsNow Podcast December 2023 - ACR23 Highlights

Dec 29, 2023

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.




  1. Abstract 0761. EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and

Read Article

AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/Hw9RECWYg5 https://t.co/A5JMCSpl0D

Dr. John Cush @RheumNow( View Tweet )
Dec 28, 2023

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Dec 27, 2023

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to 

Read Article
Best of 2023: LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/5nzq6KvOpy https://t.co/Y2MCXkGck2
Dr. John Cush @RheumNow( View Tweet )
Dec 26, 2023

Best of 2023: LAVLI - A New Autoinflammatory Disorder

Dec 21, 2023

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic

Read Article

DA Approves Canakinumab for Gout Flares The US FDA has approved canakinumab \ Ilaris\ for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. https://t.co/OX3wIajQtm https://t.co/tMDMc8ZKE8

Dr. John Cush @RheumNow( View Tweet )
Dec 20, 2023
Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77
Dr. John Cush @RheumNow( View Tweet )
Dec 16, 2023
ICYMI: Here at Last: Treatment Options for VEXAS We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to #ACR23 there has been relatively little to say about how to treat it. https://t.co/FnygxtDwx8 https://t.co/2j1nbsAAp0
Dr. John Cush @RheumNow( View Tweet )
Dec 14, 2023

IL-18 excess is assoc. w/ autoinflammatory Dz, "IL-18opathies". High IL-18 associated w/ #MAS & PSTPIP1-related diseases (eg, PAPA syndr. Pyogenic arthritis, pyoderma gangrenosum, acne)IL-18 binding protein is a biomarker of IFNγ activity. https://t.co/dy3xHdgTXX https://t.co/qBvCHvtsu7

Dr. John Cush @RheumNow( View Tweet )
Dec 14, 2023

ICYMI: Here at Last: Treatment Options for VEXAS

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been

Read Article

Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv

Dr. John Cush @RheumNow( View Tweet )
Dec 11, 2023

CBT or Naltrexone in Fibromyalgia (12.8.2023)

Dec 08, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Be sure to catch the early registration break for 2024 RheumNow Live.




  1. Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy.

Read Article
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis . https://t.co/ZU0XFecPyP https://t.co/GLPsf73Hj0
Dr. John Cush @RheumNow( View Tweet )
Dec 07, 2023

Polands disease study (sarcoidosis 78.6K; #AOSD 3294; systemic sclerosis 35.5K) betw 2009-2018. Avg hospitalization was 5.39 days sarcoidosis, 6.22 days scleroderma, & 7.44 days for Still’s (latter decr 11.7 to 5.8, betw 2008-2014) https://t.co/OcNzt7IKC5 https://t.co/uPcbOyizQN

Dr. John Cush @RheumNow( View Tweet )
Dec 07, 2023

ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease

Adult-onset Still’s disease is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis characterized by sustained fever, salmon-colored rash, and arthritis. The 2023 ACR convergence featured several abstracts spotlighting developments in

Read Article

NEW Health Policy—Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline https://t.co/WYNcVigb7n Free to read with registration on https://t.co/28wkm59DgB https://t.co/Qbm1y76o3E

The Lancet Rheumatology @TheLancetRheum( View Tweet )
Nov 30, 2023